SCYNEXIS Inc SCYX

Healthcare Biotechnology

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

NDAQ:SCYX - Post by User

SCYNEXIS Inc > Short Interest...

<< Previous

Bullboard Posts

Next >>

Post by JonathanJSmithon Jun 25, 2021 10:21am

135 Views

Post# 33450027

Short Interest...

Crazy high short interest here ( > 3.6mm shares short). I guess that's why the stock went down upon approval. I'm waiting for the EMEA contract to be finalized; with luck it'll be reported before or on the June 29th investor conference date. If so, an EMEA partnership coupled with the high short interest should light a spark under SCYX.

Cheers,

JJ

<< Previous

Bullboard Posts

Next >>

Market Open Wednesday, January 15: Commodities Lift TSX Futures as Investors Await Key Data